Vertex Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | VRTX

Vertex Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $7.648B, a 6.02% decline year-over-year.

  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $10.142B, a 55.49% increase from 2022.
  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $6.523B, a 103.79% increase from 2021.
  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $3.201B, a 272.75% increase from 2020.

Vertex Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | VRTX

  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $10.142B, a 55.49% increase from 2022.
  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $6.523B, a 103.79% increase from 2021.
  • Vertex Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $3.201B, a 272.75% increase from 2020.